Terray’s Human Algorithm: A Biotech Veteran to Guide AI Ambition

LOS ANGELES – June 15, 2026 – In the high-stakes world of AI-driven drug discovery, where algorithms promise to revolutionize medicine, the most critical component can still be a human one. Terray Therapeutics, a Los Angeles-based biotech, made this clear with its latest strategic move, appointing Lisa L. Decker, Ph.D., as its new Chief Business Officer. The announcement is more than a C-suite shuffle; it’s a calculated signal that Terray is ready to translate its formidable technological prowess into tangible commercial success and, ultimately, new medicines.

Founded on the premise that artificial intelligence could transform the slow, costly process of drug discovery, Terray has reached a pivotal moment. The company's proprietary platform, EMMI, is generating a pipeline of potential drugs and delivering results for pharmaceutical partners. Now, the challenge is to scale that success. As CEO Jacob Berlin stated, “Lisa will be an incredible asset and catalyst for our next stage as we evaluate opportunities for our medicines and continue to expand the impact of our platform across the pharma ecosystem.” His choice of the word “catalyst” is telling—Decker isn't just joining the team; she's been brought in to accelerate a reaction.

The Architect of Alliances

To understand the significance of this hire, one need only look at Lisa Decker's resume, which reads like a masterclass in biotech business development. With over two decades of experience, she has a reputation for orchestrating the kind of multi-billion-dollar partnerships that can define a company's trajectory. Her recent tenure as Chief Business Officer at IGM Biosciences, for example, was marked by a landmark 2022 collaboration with Sanofi, a deal potentially worth over $6 billion, focused on developing antibody agonists for oncology and immunology.

Before that, she honed her skills at Atreca and spent over a decade at Nektar Therapeutics, where she was involved in a strategic oncology collaboration with Bristol-Myers Squibb valued at up to $3.6 billion. This track record demonstrates a rare ability to bridge the gap between complex science and commercial strategy, building the trust and financial frameworks necessary for long-term development. One industry analyst noted that Decker is known for her “sophisticated business and science acumen alongside a mission-driven approach,” a combination Terray is clearly betting on.

Her background is also a perfect strategic fit. With a Ph.D. in Immunology, Decker possesses deep domain expertise in Terray’s primary internal focus: developing a proprietary pipeline of small-molecule therapeutics for patients with autoimmune diseases. Her appointment is not just about making deals; it’s about making the right deals, guided by a genuine understanding of the science and the unmet needs of patients. As Decker herself noted, the dual potential of Terray’s platform to “deliver for partners on their challenging targets and build a proprietary pipeline” is “incredibly exciting.”

Inside the Data Engine

Decker arrives at a company that has built one of the most powerful engines in the industry. Terray’s competitive edge lies in its EMMI (Emergent Multimodal Molecular Intelligence) platform, a tightly integrated, closed-loop system that marries massive-scale experimentation with full-stack AI. Unlike some competitors that focus primarily on computational modeling, Terray has invested heavily in its own wet-lab capabilities, adopting a “chemistry-first” approach.

The scale is staggering. The company reports that it has quantitatively measured over five billion target-ligand interactions, creating a proprietary dataset roughly 50 times the size of all publicly available chemistry data. This firehose of high-quality, real-world information feeds its machine learning models, allowing Terray’s scientists to rapidly design, synthesize, and test novel molecules in a virtuous cycle of digital prediction and physical validation. This approach aims to solve one of AI’s fundamental challenges: the “garbage in, garbage out” problem. By generating its own pristine data, Terray ensures its AI models are learning from a clear and accurate picture of molecular reality.

This integrated system has already attracted powerful allies. The company has raised over $200 million from a syndicate of top-tier investors, including Madrona Venture Group, Lightspeed Venture Partners, and the venture arms of industry giants NVIDIA (NVentures) and Pfizer. These investments are more than just capital; they are a vote of confidence in Terray’s unique strategy and a validation of its technological foundation.

From Code to Clinic

The timing of Decker’s arrival is critical. The entire field of AI drug discovery is at an inflection point. After years of hype and billions in investment, the industry is under pressure to deliver on its promise of getting novel drugs to market faster and cheaper. While numerous AI-designed candidates are now in clinical trials, none have yet crossed the finish line to regulatory approval. In this “prove it” moment, the ability to forge strong, value-generating partnerships is paramount.

Decker’s primary mission will be to leverage Terray's platform and its early successes with partners like Calico and Bristol Myers Squibb to build a sustainable ecosystem of collaboration. These partnerships provide non-dilutive capital, offer external validation of the platform’s capabilities, and allow Terray to tackle a broader range of diseases than it could alone. Her expertise will be crucial in structuring deals that advance partner programs while protecting the value of Terray’s internal pipeline.

Ultimately, this story is about humanizing the digital frontier of medicine. Behind the billions of data points and complex algorithms is a clear goal: creating new treatments for debilitating conditions. The appointment of a seasoned leader like Lisa Decker is a recognition that even the most powerful technology requires human wisdom, strategic vision, and a relentless focus on the mission. It is a bet that the right human catalyst can transform digital potential into life-changing reality for patients.